A randomized, open-label, two-period crossover study to evaluate the bioequivale...

연구 요약

A randomized, open-label, two-period crossover study to evaluate the bioequivalence and food effect between two formulations of regorafenib in healthy adult participants.

Frontiers in pharmacology 학술지에 발표된 이 연구는 Li Y, Qi L, Yang C 외 연구팀이 수행하였습니다.

이 연구는 'A randomized, open-label, two-period crossover study to evaluate the bioequivalence and food effect between two formulations of regorafenib in healthy adult participants.'에 대한 과학적 분석을 제공합니다.

핵심 내용

BACKGROUND: This research aimed to compare the bioequivalence of a test formulation (regorafenib produced by Beijing SL Pharmaceutical Co., Ltd.) with a reference formulation (the original drug Stivarga®) in Chinese healthy subjects under fasting conditions and two postprandial states: after low-fat and high-fat meals. METHODS: The research design was a randomized, open-label, two-period crossover trial involving a single 40 mg oral dose. Three separate studies were conducted. Study 1 enrolled 64 subjects who were dosed under fasting conditions; Study 2 involved 76 subjects dosed after a low-fat breakfast; and Study 3 also involved 76 subjects dosed after a high-fat breakfast. Plasma concentrations of regorafenib and M-2 were determined using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The primary endpoints were the peak plasma concentration (Cmax), the area under the concentration-time curve from time 0 to 168 h (AUC0-168h), and the extrapolated area under the curve from time zero to infinity (AUC0-∞) of regorafenib, with pharmacokinetics (PK) parameters of the metabolite M-2 serving as reference data. RESULTS: The results showed that, under fasting, post-low-fat meal, and post-high-fat meal conditions, the 90% confidence intervals (CIs) of geometric mean ratios (GMRs) for Cmax of test to reference regorafenib were 96.39%-114.94%, 93.81%-106.67% and 94.23%-107.21%, respectively. For AUC0-168h were 88.40%-102.04%, 92.40%-102.97% and 92.50%-102.60%. For AUC0-∞ were 85.86%-100.01%, 90.26%-101.79% and 90.15%-101.36%. All of these fell within the 80.00%-125.00% range, meeting the equivalence criteria. Food intake had some impact on the PK parameters of regorafenib, but the effect was minor. Administration of a single 40 mg dose of regorafenib to healthy subjects demonstrated good safety and tolerability. CONCLUSION: Under different dietary conditions, a single oral dose of 40 mg of generic drug regorafenib was bioequivalent to the original drug Stivarga® in healthy Chinese subjects, and the food effect was limited. CLINICAL TRIAL REGISTRATION: http://www.chinadrugtrials.org.cn/, identifier CTR20210575, CTR20210576, CTR20223278.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 40176915)

📄 [전문 보기 (Markdown)](fulltext/40176915-a-randomized-open-label-two-period-crossover-study-to-evalua.md)